3 Oilfield Services Stocks Poised to Gain Despite Industry Challenges
Strict capital discipline by upstream energy companies is acting as a dampener, making the outlook for the Zacks Oil and Gas-Field Services industry gloomy. FTI, OII and CLB are expected to survive the industry woes.
Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results?
Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
Core Laboratories Q2 Earnings Call Highlights
Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly offset disruptions to its service business from conflicts in the Middle East and Russia-Ukraine.
Core Laboratories (CLB) Q2 Earnings Surpass Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.19 per share a year ago.
What's in Store for Core Laboratories Stock in Q2 Earnings?
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Core Stock Down 39% in 6 Months: Should You Hold or Sell Now?
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.
Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?
CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delayed shipments, limiting visibility into a stronger recovery.
Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Implied Volatility Surging for Core Laboratories Stock Options
Investors need to pay close attention to CLB stock based on the movements in the options market lately.
